Bionor Pharma ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bionor Pharma ASA Appoints Dr. Anker Lundemose New President and Chief Executive Officer
Bionor Pharma ASA announced that Dr. Anker Lundemose has been appointed new President and Chief Executive Officer (CEO) of Bionor Pharma ASA from March 1, 2013. Dr. Lundemose replaces Mr. Steen Kroyer, who has held the position of Interim CEO of the Company since September 2011, and who will take the position of Deputy Chairman of the Board of Directors in accordance with the nomination and election at the Company's Annual General Meeting of May 11, 2012.
Latest Developments for Bionor Pharma ASA
- Bionor Pharma says results from Vacc-4x Phase II Reboost trial reconfirms 2010 study
- Bionor Pharma ASA announces positive results from vaccine Vacc-C5 Phase I
- Bionor Pharma announces potential biomarker for reduction of Viral Load Identified for Vacc-4x
- Bionor Pharma ASA Completes Private Placement and Proposes Repair Offer
Latest Key Developments in Food
- WhiteWave Foods Company completes acquisition of So Delicious Dairy Free
- Boso Oil&Fat Co Ltd raises consolidated mid-year outlook for FY 2015
- Nihon Shokuhin Kako Co Ltd lowers consolidated full-year outlook for FY 2015 and announces dividend forecast not changed for FY 2015
- Imuraya Group Co Ltd amends consolidated mid-year outlook for FY 2015
- Share this
- Digg this